{"protocolSection": {"identificationModule": {"nctId": "NCT06497556", "orgStudyIdInfo": {"id": "BO45217"}, "secondaryIdInfos": [{"id": "2024-510908-37-00", "type": "OTHER", "domain": "EU CT Number"}], "organization": {"fullName": "Hoffmann-La Roche", "class": "INDUSTRY"}, "briefTitle": "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer", "officialTitle": "A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer", "acronym": "Krascendo 1"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hoffmann-La Roche", "class": "INDUSTRY"}, "collaborators": [{"name": "Chugai Pharmaceutical", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC)."}, "conditionsModule": {"conditions": ["Non-Small Cell Lung Cancer", "KRAS G12C Lung Cancer"], "keywords": ["Advanced Non-Small Cell Lung Cancer", "KRAS G12 Lung Cancer", "Advanced Lung Cancer", "Metastatic lung cancer", "Divarasib", "KRAS G12C Inhibitor", "KRAS G12C Positive", "KRAS Mutation", "KRAS G12C Mutation", "Lung Cancer Mutation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 320, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Divarasib", "type": "EXPERIMENTAL", "description": "Participants will receive divarasib orally, once daily (QD).", "interventionNames": ["Drug: Divarasib"]}, {"label": "KRAS G12C inhibitor", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive Sotorasib orally QD or adagrasib orally twice a day (BID)", "interventionNames": ["Drug: Sotorasib", "Drug: Adagrasib"]}], "interventions": [{"type": "DRUG", "name": "Divarasib", "description": "Divarasib will be administered orally QD", "armGroupLabels": ["Divarasib"]}, {"type": "DRUG", "name": "Sotorasib", "description": "Sotorasib will be administered orally QD", "armGroupLabels": ["KRAS G12C inhibitor"]}, {"type": "DRUG", "name": "Adagrasib", "description": "Adagrasib will be administred orally BID", "armGroupLabels": ["KRAS G12C inhibitor"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Unequivocal histologically or cytologically confirmed diagnosis of metastatic or locally advanced NSCLC not amenable to treatment with surgical resection or combined chemoradiation\n* Disease progression during or after treatment with at least one prior systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Documentation of the presence of a KRAS G12C mutation\n* Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshly cut, serial slides with an associated pathology report\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy of \\>= 12 weeks\n\nExclusion Criteria:\n\n* Known hypersensitivity to any of the components of divarasib, or sotorasib or adagrasib\n* Malabsorption syndrome or other condition that would interfere with enteral absorption\n* Known concomitant second oncogenic driver\n* Mixed small-cell lung cancer or large cell neuroendocrine histology\n* Known and untreated, or active central nervous system (CNS) metastases\n* Leptomeningeal disease or carcinomatous meningitis\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently\n* Any infection that, in the opinion of the investigator, could impact patient safety, or treatment with therapeutic oral or IV antibiotics within 14 days prior to Day 1 of Cycle 1\n* Prior treatment with any KRAS G12C inhibitor or pan-KRAS/RAS inhibitor\n* More than 30 Gy of radiotherapy to the lung within 6 months of randomization\n* Uncontrolled tumor-related pain\n* Unresolved toxicities from prior anticancer therapy\n* History of malignancy within 5 years prior to screening, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Reference Study ID Number: BO45217 https://forpatients.roche.com/", "role": "CONTACT", "phone": "888-662-6728 (U.S. and Canada)", "email": "global-roche-genentech-trials@gene.com"}], "overallOfficials": [{"name": "Clinical Trials", "affiliation": "Hoffmann-La Roche", "role": "STUDY_DIRECTOR"}]}}, "hasResults": false}